Items Tagged ‘tnbc’

June 30th, 2016

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer

By

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to […]

View full entry

Tags: Breast Cancer, immunotherapy, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Tecentriq, tnbc, Triple Negative Breast Cancer


March 24th, 2016

Complete Pathologic Responses Associated with Prognosis in Triple-Negative Breast Cancer

By

A complete pathologic response (no cancer cells detected through microscopic evaluation) appears to be the most accurate indicator of long-term prognosis for women with triple-negative breast cancer. These results were recently presented at the 2015 annual meeting of the San Antonio Breast Cancer Symposium (SABCS). Approximately 10-20% of breast cancers are referred to as triple-negative […]

View full entry

Tags: Breast Cancer, complete pathologic response, HER2-negativeresearch, long-term prognosis, News, pCR, tnbc, Triple Negative Breast Cancer


January 7th, 2016

Atezolizumab Plus Abraxane Promising New Treatment for Triple-Negative Breast Cancer

By

The investigative agent, atezolizumb, in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. These results were recently presented at the 2015 annual San Antonio Breast Cancer Symposium. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both […]

View full entry

Tags: abraxane, atezolizumab, Breast Cancer, News, tnbc, Triple Negative Breast Cancer


December 23rd, 2015

Abraxane® Combo Promising in Triple Negative Breast Cancer

By

The chemotherapy combination consisting of Abraxane® (nab-paclitaxel) plus carboplatinum (carbo) improves outcomes compared with Abraxane plus Gemzar (gemcitabine) for triple negative breast cancer. These results were presented at the 2015 annual San Antonio Breast Cancer Symposium (SABCS). Approximately 10-20% of breast cancers are referred to as triple negative breast cancer (TNBC). These types of cancers […]

View full entry

Tags: abraxane, Breast Cancer, gemzar, News, tnbc, Triple Negative Breast Cancer


December 22nd, 2015

Adding Carboplatin to Pre-surgery Chemotherapy Improves Survival for Patients with Triple-Negative Breast Cancer

By

Adding carboplatin to pre-surgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from a German clinical study released at the San Antonio Breast Cancer Symposia.1 Breast cancers that are not stimulated to grow from exposure to estrogen or progesterone and are HER2 (human epidermal growth factor receptor)-negative are called […]

View full entry

Tags: Breast Cancer, carboplatin, HER2-negative, News, surgery, tnbc, Triple Negative Breast Cancer


December 10th, 2014

Initial Results of PD-1 Checkpoint Inhibitors Evaluated in Triple-Negative Breast Cancer Presented in San Antonio

By

The initial results from a phase 1 trial evaluating the checkpoint inhibitor Keytruda® (pembrolizumab) in patients with heavily pretreated triple-negative breast cancer were recently reported at the San Antonio Breast Cancer Symposium (SABCS). The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune […]

View full entry

Tags: Breast Cancer, immunotherapy, keytruda, Metastatic Breast Cancer, News, PD-1, Recurrent Breast Cancer, tnbc, Triple Negative Breast Cancer